
    
      This extension study will include participants up to 60 participants with acromegaly from
      Study NCT03548415. All participants will remain on the same dose from the previous study and
      receive IONIS GHR-LRx (SC) injection once every 28 days as add-on to SRL therapy for 53
      weeks. At the end of 53 weeks, participants will enter a 14-week post-treatment (PT)
      evaluation period.
    
  